Devyser has today been certified under the new, more comprehensive IVD Regulation that came into force on
From
"We have worked intensively over the past two years to meet the more comprehensive requirements of the IVD Regulation. Our customers can be reassured to know that our fetal diagnostics product has already been approved. Further, it shows that Devyser has a development and quality organization that can compete with the best in
In
"The transition to the IVD Regulation is a major challenge for the industry in general. This certification is a sign of our relentless commitment to and focus on quality and patient safety. We are proud to be able to offer our customers this assurance," says
This is information that
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 706 673 106
Email: sabina.berlin@devyser.com
Telephone: +46 739 519 502
About
Devyser develops, produces, and sells genetic testing kits to laboratories in more than 45 countries. The products are used for advanced DNA testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient monitoring. Devyser's products simplify complex genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. The company was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
https://news.cision.com/devyser-diagnostics-ab/r/devyser-s-quality-management-system-and-fetal-diagnostics-product-approved-under-the-new-european-iv,c3622188
https://mb.cision.com/Main/13649/3622188/1620404.pdf
(c) 2022 Cision. All rights reserved., source